ARCHIVES

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

ASCO and CAP Issue Guideline To Improve HER2 Testing

October 25, 2013

In Brief: Shingleton “Unretires” As Director Of Duke Center; O’Brien Interim Head At USC When Hammond Leave

July 24, 1981

DRG Reimbursement Schedules Estimated for High, Low Areas; City Of Hope Added to Exemptions, Other Without Much Hope

November 18, 1983

Supplements Reduce Deaths In NCI Studies In China “JNCI”

September 17, 1993

Early Clinical Trials Of Targeted Therapies Highlighted At AACR-NCI-EORTC Meeting

October 26, 2007